BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, Yagi et al. reported that the specific activation of STAT3 in CML and the combined inhibition of JAK1 with tofacitinib and BCR::ABL1 with imatinib synergistically induced anti-tumour effects in CML cells [102].